RU94042722A - Химерный белок, ген, клетка, вектор, способ получения химерного белка, вакцина - Google Patents

Химерный белок, ген, клетка, вектор, способ получения химерного белка, вакцина

Info

Publication number
RU94042722A
RU94042722A RU94042722/13A RU94042722A RU94042722A RU 94042722 A RU94042722 A RU 94042722A RU 94042722/13 A RU94042722/13 A RU 94042722/13A RU 94042722 A RU94042722 A RU 94042722A RU 94042722 A RU94042722 A RU 94042722A
Authority
RU
Russia
Prior art keywords
chimeric protein
pathogen
gene sequence
gene
vaccine
Prior art date
Application number
RU94042722/13A
Other languages
English (en)
Other versions
RU2123047C1 (ru
Inventor
Х.Клейн Мишел
Ca]
Ду Рун-Пан
Е.Эвазишин Мери
Original Assignee
Коннот Лабораториз Лимитед (CA)
Коннот Лабораториз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Коннот Лабораториз Лимитед (CA), Коннот Лабораториз Лимитед filed Critical Коннот Лабораториз Лимитед (CA)
Publication of RU94042722A publication Critical patent/RU94042722A/ru
Application granted granted Critical
Publication of RU2123047C1 publication Critical patent/RU2123047C1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/135—Respiratory syncytial virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Мультимерные гибридные гены, кодирующие соответствующий химерный белок, включают в себя генную последовательность, кодирующую антигенную область белка от первого патогена, и связанную с генной последовательностью, кодирующей антигенную область белка от второго патогена. Такими патогенами являются в частности парагриппозный вирус (ПГВ) и респираторно-синцитиальный вирус (РСВ). Единый рекомбинантный иммуноген способен обеспечивать иммунную защиту детей и других восприимчивых индивидуумов от заболеваний, вызываемых обоими ПГВ и РСВ - вирусами.

Claims (1)

  1. Мультимерные гибридные гены, кодирующие соответствующий химерный белок, включают в себя генную последовательность, кодирующую антигенную область белка от первого патогена, и связанную с генной последовательностью, кодирующей антигенную область белка от второго патогена. Такими патогенами являются в частности парагриппозный вирус (ПГВ) и респираторно-синцитиальный вирус (РСВ). Единый рекомбинантный иммуноген способен обеспечивать иммунную защиту детей и других восприимчивых индивидуумов от заболеваний, вызываемых обоими ПГВ и РСВ - вирусами.
RU94042722A 1992-01-06 1993-01-05 Гибридный белок, гибридный ген, способ получения гибридного белка, вакцина против вирусных заболеваний верхних дыхательных путей, бакуловирусный вектор экспрессии (варианты) RU2123047C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929200117A GB9200117D0 (en) 1992-01-06 1992-01-06 Production of recombinant chimeric proteins for vaccine use
GB9200117.1 1992-01-06

Publications (2)

Publication Number Publication Date
RU94042722A true RU94042722A (ru) 1996-09-10
RU2123047C1 RU2123047C1 (ru) 1998-12-10

Family

ID=10708117

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94042722A RU2123047C1 (ru) 1992-01-06 1993-01-05 Гибридный белок, гибридный ген, способ получения гибридного белка, вакцина против вирусных заболеваний верхних дыхательных путей, бакуловирусный вектор экспрессии (варианты)

Country Status (16)

Country Link
US (13) US6225091B1 (ru)
EP (1) EP0621898B1 (ru)
JP (1) JP3290662B2 (ru)
KR (1) KR100208310B1 (ru)
AT (1) ATE205535T1 (ru)
AU (1) AU667502B2 (ru)
CA (1) CA2126863C (ru)
DE (1) DE69330745T2 (ru)
DK (1) DK0621898T3 (ru)
ES (1) ES2164070T3 (ru)
FI (1) FI117514B (ru)
GB (1) GB9200117D0 (ru)
NO (1) NO316622B1 (ru)
PT (1) PT621898E (ru)
RU (1) RU2123047C1 (ru)
WO (1) WO1993014207A1 (ru)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
KR100658491B1 (ko) 1996-07-15 2006-12-18 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 클론닝된 뉴클레오타이드 서열로부터 약독화된 호흡기 세포 융합 바이러스 백신의 생산
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US7250171B1 (en) 1997-05-23 2007-07-31 United States Of America As Represented By The Dept. Of Health & Human Services Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7314631B1 (en) 1997-05-23 2008-01-01 The United States Of America As Represented By The Department Of Health And Human Services Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
WO2000018929A2 (en) * 1998-09-25 2000-04-06 Smithkline Beecham Biologicals S.A. Paramyxovirus vaccines
KR100905450B1 (ko) 1999-07-09 2009-07-02 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 약독화된 인간-소 키메릭 호흡기 신시티움 바이러스백신의 제조 방법
CN101392239A (zh) * 1999-07-09 2009-03-25 美国政府健康及人类服务部 减毒的人-牛嵌合副流感病毒(piv)疫苗
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
UA93981C2 (ru) 2001-01-19 2011-03-25 Вироновативе Б.B. Вирус, который вызывает заболевание дыхательных путей у чувствительных k этому млекопитающих
WO2003072720A2 (en) 2002-02-21 2003-09-04 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
JP4448440B2 (ja) * 2002-04-30 2010-04-07 株式会社ディナベック研究所 プロテアーゼ依存性トロピズムが改変されたベクター
TW200501985A (en) * 2002-07-25 2005-01-16 Medimmune Inc Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
WO2004066961A2 (en) * 2003-01-20 2004-08-12 St. Jude Children's Research Hospital Use of sendai virus as a human parainfluenza vaccine
WO2004087062A2 (en) * 2003-03-28 2004-10-14 Medimmune Vaccines, Inc. Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
US7704720B2 (en) 2003-04-25 2010-04-27 Medimmune, Llc Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
EP1841785A2 (en) * 2005-01-19 2007-10-10 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
CA2638760A1 (en) * 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
DE102006060799A1 (de) 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
WO2010086743A2 (en) 2009-02-02 2010-08-05 Chrontech Pharma Ab Compositions and methods that enhance an immune response
WO2010149743A2 (en) * 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine
CA2825722A1 (en) * 2011-01-28 2012-08-02 Medimmune, Llc Expression of soluble viral fusion glycoproteins in mammalian cells
WO2013031827A1 (ja) 2011-08-29 2013-03-07 国立大学法人徳島大学 Rsv粘膜ワクチン
US9662379B2 (en) 2011-12-02 2017-05-30 Rhode Island Hospital Vaccine for falciparum malaria
KR20220119527A (ko) 2012-08-01 2022-08-29 버베리안 노딕 에이/에스 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신
US20160324954A1 (en) 2013-05-15 2016-11-10 Chrontech Pharma Ab Immunogenic compositions for inhibiting hepatitis d virus
HUE059127T2 (hu) 2015-10-22 2022-10-28 Modernatx Inc Légúti vírusok elleni vakcinák
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
US20200030432A1 (en) 2017-03-17 2020-01-30 Modernatx, Inc. Zoonotic disease rna vaccines
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
EP0175261B1 (en) * 1984-09-12 1991-12-11 Chiron Corporation Hybrid particle immunogens
US4722898A (en) * 1985-04-29 1988-02-02 Minnesota Mining And Manufacturing Company Immobilization of biological cells in polytetrafluoroethylene matrix
GB8610983D0 (en) * 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5098998A (en) * 1987-04-29 1992-03-24 President And Fellows Of Harvard College Cholera vaccines and peptides
EP0316695B1 (de) * 1987-11-16 1993-03-31 F. Hoffmann-La Roche Ag Rekombinante HIV-2 Polypeptide
JP2716503B2 (ja) * 1987-12-23 1998-02-18 ジ・アップジョン・カンパニー ヒト呼吸系シンシチウムウイルスの糖蛋白類の免疫原性セグメントを含有するキメラ糖蛋白類
ATE105334T1 (de) * 1988-04-22 1994-05-15 Upjohn Co Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
FR2636842B1 (fr) 1988-09-27 1994-06-10 Liege Universite Etat Proteine de fusion d'une sequence derivee de la sous-unite b de la toxine cholerique et d'un antigene heterologue doue de proprietes immunogenes, compositions de vaccins les contenant et acides nucleiques recombinants contenant une sequence de nucleotides codant pour ladite proteine de fusion
EP0421626A1 (en) 1989-09-19 1991-04-10 Merck & Co. Inc. Vaccine for aids and hepatitis B
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus

Also Published As

Publication number Publication date
JP3290662B2 (ja) 2002-06-10
FI117514B (fi) 2006-11-15
US5968776A (en) 1999-10-19
US20080311624A1 (en) 2008-12-18
RU2123047C1 (ru) 1998-12-10
US6017539A (en) 2000-01-25
US6171783B1 (en) 2001-01-09
US20080015340A1 (en) 2008-01-17
US20080032342A1 (en) 2008-02-07
NO942530L (no) 1994-09-05
FI943211A (fi) 1994-09-02
NO942530D0 (no) 1994-07-05
CA2126863A1 (en) 1993-07-22
KR100208310B1 (ko) 1999-07-15
AU667502B2 (en) 1996-03-28
US20050136067A1 (en) 2005-06-23
CA2126863C (en) 1999-08-10
US20080312412A1 (en) 2008-12-18
FI943211A0 (fi) 1994-07-05
PT621898E (pt) 2002-03-28
US7514535B2 (en) 2009-04-07
ES2164070T3 (es) 2002-02-16
US7244589B2 (en) 2007-07-17
GB9200117D0 (en) 1992-02-26
EP0621898A1 (en) 1994-11-02
ATE205535T1 (de) 2001-09-15
US7671186B2 (en) 2010-03-02
JPH07501707A (ja) 1995-02-23
US6168786B1 (en) 2001-01-02
US7619063B2 (en) 2009-11-17
AU3340293A (en) 1993-08-03
NO316622B1 (no) 2004-03-15
EP0621898B1 (en) 2001-09-12
DE69330745T2 (de) 2002-05-29
US7498153B2 (en) 2009-03-03
WO1993014207A1 (en) 1993-07-22
DK0621898T3 (da) 2001-11-12
US6225091B1 (en) 2001-05-01
US6033668A (en) 2000-03-07
US5998169A (en) 1999-12-07
US20080027213A1 (en) 2008-01-31
DE69330745D1 (de) 2001-10-18
US7405273B2 (en) 2008-07-29

Similar Documents

Publication Publication Date Title
RU94042722A (ru) Химерный белок, ген, клетка, вектор, способ получения химерного белка, вакцина
Lin et al. Absence of M protein in a cell-associated subacute sclerosing panencephalitis virus
Wiktor et al. Human cell culture rabies vaccine: antibody response in man
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
DK0584348T3 (da) Genetisk vaccine mod immundefektvirusser
Harmon et al. Therapy of murine rabies after exposure: efficacy of polyriboinosinic-polyribocytidylic acid alone and in combination with three rabies vaccines
Wiktor et al. Immunogenic properties of vaccinia recombinant virus expressing the rabies glycoprotein
EP0402029B1 (en) Monoclonal antibodies for post exposure treatment of rabies
KR890700030A (ko) 인플루엔자균(Haemophilus influenzae)의 백신 및 진단방법
SE9202968D0 (sv) New peptides, diagnostic antigens, use thereof, vaccines and medicaments
ALLEN et al. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity
WO2002057314A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes
Pedersen Jr et al. Separation, isolation, and immunological studies of the structural proteins of Venezuelan equine encephalomyelitis virus
Virelizier et al. The role of humoral immunity in host defence against influenza A infection in mice
Lafon et al. Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
CA2075366A1 (en) Immunologically active peptides or polypeptides from the parvovirus b19
AU3379693A (en) Vaccines and diagnostic assays for haemophilus influenzae
CN108727503A (zh) VZV重组gE-鞭毛素融合蛋白及其制备方法和应用
WO2004005316A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
ATE283065T1 (de) Mehrzweckvakzine gegen umhüllte viren
YU45292A (sh) Različiti površinski proteini hepatitis b virusa koji obrazuju čestice
JACOBSON et al. Induction of measles virus-specific human cytotoxic T cells by purified measles virus nucleocapsid and hemagglutinin polypeptides
JPH03135923A (ja) 百日咳毒素ｂオリゴマーの構成サブユニットを含有する経鼻接種ワクチン
Zanetti et al. Failure of protection induced by a Brazilian vaccine against Brazilian wild rabies viruses